- Home
- ABSI vs TNGX Comparison
ABSI vs TNGX Comparison
Compare ABSI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- TNGX
- Stock Information
- Founded
- ABSI 2011
- TNGX 2014
- Country
- ABSI United States
- TNGX United States
- Employees
- ABSI N/A
- TNGX N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- TNGX Health Care
- Exchange
- ABSI Nasdaq
- TNGX Nasdaq
- Market Cap
- ABSI 457.6M
- TNGX 413.6M
- IPO Year
- ABSI 2021
- TNGX N/A
- Fundamental
- Price
- ABSI $3.01
- TNGX $3.04
- Analyst Decision
- ABSI Strong Buy
- TNGX Strong Buy
- Analyst Count
- ABSI 6
- TNGX 8
- Target Price
- ABSI $8.67
- TNGX $13.14
- AVG Volume (30 Days)
- ABSI 2.4M
- TNGX 1.5M
- Earning Date
- ABSI 11-12-2024
- TNGX 11-06-2024
- Dividend Yield
- ABSI N/A
- TNGX N/A
- EPS Growth
- ABSI N/A
- TNGX N/A
- EPS
- ABSI N/A
- TNGX N/A
- Revenue
- ABSI $4,207,000.00
- TNGX $43,383,000.00
- Revenue This Year
- ABSI $8.57
- TNGX $27.73
- Revenue Next Year
- ABSI $169.72
- TNGX N/A
- P/E Ratio
- ABSI N/A
- TNGX N/A
- Revenue Growth
- ABSI N/A
- TNGX 15.67
- 52 Week Low
- ABSI $2.45
- TNGX $2.70
- 52 Week High
- ABSI $6.72
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- ABSI 44.56
- TNGX 39.30
- Support Level
- ABSI $2.79
- TNGX $2.72
- Resistance Level
- ABSI $4.11
- TNGX $3.29
- Average True Range (ATR)
- ABSI 0.42
- TNGX 0.30
- MACD
- ABSI -0.04
- TNGX 0.07
- Stochastic Oscillator
- ABSI 12.28
- TNGX 32.08
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.